Form 4: Denali Therapeutics Chief Medical Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Denali Therapeutics' Chief Medical Officer, Carole Ho, sold shares to cover tax obligations related to vested restricted stock units.
Summary
- Carole Ho, Chief Medical Officer of Denali Therapeutics, sold 12,255 shares of common stock on January 6, 2025, at a weighted average price of $20.22 per share.
- She sold an additional 2,907 shares on January 7, 2025, at a price of $20.81 per share.
- These sales were made to satisfy tax obligations arising from the settlement of previously vested restricted stock units.
- Following these transactions, Ms. Ho directly owns 175,673 shares of common stock, which includes 134,030 unvested RSUs.
- She also indirectly owns 183,219 shares through the Rohatgi-Ho Family 2009 Revocable Trust and 25,000 shares through The Rohatgi-Ho Irrevocable GST Trust.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction for tax purposes and does not indicate any positive or negative sentiment towards the company's performance.
Risks
- Sales of shares by company officers can sometimes be perceived negatively by the market, although these sales were for tax obligations.
Industry Context
This is a routine filing related to insider transactions and is common for executives who receive stock-based compensation. It does not indicate any change in the company's operations or outlook.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, and this transaction is consistent with typical executive stock sales for tax purposes.
- Other biotech companies such as Biogen and Amgen also have similar filings when their executives sell shares.
Stakeholder Impact
- The stock sales may have a minor impact on the stock price, but it is unlikely to be significant as it is a routine transaction.
Key Dates
| Date | Description |
|---|---|
| 01/06/2025 | Sale of 12,255 shares of common stock at a weighted average price of $20.22. |
| 01/07/2025 | Sale of 2,907 shares of common stock at a price of $20.81. |
| 01/08/2025 | Date of signature for the Form 4 filing. |
Keywords
Denali Therapeutics, Carole Ho, Chief Medical Officer, stock sale, Form 4, insider trading, restricted stock units, tax obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.